No Data
Zeria Pharmaceutical: Confirmation letter
Zeria Pharmaceutical: Half-Year Report - Term 71 (2024/04/01 - 2025/03/31)
JFE, downward revision on 25/3, operating profit of 160 billion yen ← 260 billion yen
JFE <5411> announced a revision to the financial estimates for the fiscal year ending March 2025. The sales revenue was revised downward from 5 trillion 240 billion yen to 4 trillion 970 billion yen, and the operating profit was revised downward from 260 billion yen to 160 billion yen. In the iron & steel business, further demand deceleration is expected due to rising construction costs and labor shortages in the domestic building materials sector, as well as stagnation in demand for steel for Asia-bound automobiles, with the standalone crude steel production volume expected to be around 22.4 million tons, which is 0.6 million tons lower than the previous forecast. [Positive Evaluation] <9001>
Zeria Pharmaceutical: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [Japanese GAAP] (consolidated)
Zeria Pharmaceutical 1H Net Y6.06B Vs Net Y5.40B
Toyota, Itochu, NYK Line, Nitori Holdings (6th)
※The above calendar is only a schedule and may be subject to change depending on the company's circumstances.---------------------------------------November 6th (Wed) <1301> Kyokuyo <1332> Nissui <1420> Sanyo H <165A> SBI Leos <1799> Daiichi Construction <1814> Oomatsu Ken <1884> Nichi Doro <1898> Seiki Tokyu <196
No Data
No Data